Apple And Salesforce Lead The DIA In A Mixed Day Of Trading
U.S. indices had a mixed day of trading Thursday as traders and investors weigh COVID-19 variant updates, recent earnings and the recently passed $1 trillion infrastructure bill.
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 11)
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck’s Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 9)
FDA Accepts Application for Merck’s KEYTRUDA as Single Agent for Certain Patients With MSI-H/dMMR Advanced Endometrial Carcinoma
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA)
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA as Adjuvant Therapy in Certain Patients With Renal Cell Carcinoma Following Surgery
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License
Moderna Is Now Valued Higher Than 130-Year Old Vaccine Giant Merck
Moderna Inc (NASDAQ: MRNA), a company founded in 2010, is now worth more than the 130-year old Merck & Co., Inc (NYSE: MRK) in terms of market capitalization.
Analyzing Merck & Co’s Unusual Options Activity
On Monday, shares of Merck & Co (NYSE:MRK) saw unusual options activity. After the option alert, the stock price moved up to $75.89.
Unusual Options Activity Insight: Merck & Co
Shares of Merck & Co (NYSE:MRK) saw some unusual options activity on Thursday. Following the unusual option alert, the stock price moved down to $75.13.
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)